169 related articles for article (PubMed ID: 34938177)
1. Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer.
Mitra Ghosh T; White J; Davis J; Mazumder S; Kansom T; Skarupa E; Barnett GS; Piazza GA; Bird RC; Mitra AK; Yates C; Cummings BS; Arnold RD
Front Pharmacol; 2021; 12():736951. PubMed ID: 34938177
[TBL] [Abstract][Full Text] [Related]
2. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.
Aljuffali IA; Mock JN; Costyn LJ; Nguyen H; Nagy T; Cummings BS; Arnold RD
Cancer Biol Ther; 2011 Sep; 12(5):407-20. PubMed ID: 21709443
[TBL] [Abstract][Full Text] [Related]
4. Identification of key genes and pathways associated with topotecan treatment using multiple bioinformatics tools.
Kang YM; Lan A; Huang YH; Hsu KM; Chao Y; Lan KL
J Chin Med Assoc; 2020 May; 83(5):446-453. PubMed ID: 32243271
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel key genes associated with the metastasis of prostate cancer based on bioinformatics prediction and validation.
Song F; Zhang Y; Pan Z; Hu X; Yi Y; Zheng X; Wei H; Huang P
Cancer Cell Int; 2021 Oct; 21(1):559. PubMed ID: 34696780
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
Yan Y; Mao X; Zhang Q; Ye Y; Dai Y; Bao M; Zeng Y; Huang R; Mo Z
Cancer Biomark; 2021; 31(1):87-96. PubMed ID: 33780364
[TBL] [Abstract][Full Text] [Related]
9. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
Mialon A; Sankinen M; Söderström H; Junttila TT; Holmström T; Koivusalo R; Papageorgiou AC; Johnson RS; Hietanen S; Elenius K; Westermarck J
Mol Cell Biol; 2005 Jun; 25(12):5040-51. PubMed ID: 15923621
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Jonsson E; Fridborg H; Csóka K; Dhar S; Sundström C; Nygren P; Larsson R
Br J Cancer; 1997; 76(2):211-9. PubMed ID: 9231921
[TBL] [Abstract][Full Text] [Related]
12. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
13. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
14. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
16. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
Chow A; Wong A; Francia G; Man S; Kerbel RS; Emmenegger U
Invest New Drugs; 2014 Feb; 32(1):47-59. PubMed ID: 23728939
[TBL] [Abstract][Full Text] [Related]
17. Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer.
Pang X; Xie R; Zhang Z; Liu Q; Wu S; Cui Y
Front Oncol; 2019; 9():924. PubMed ID: 31620371
[TBL] [Abstract][Full Text] [Related]
18. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
[No Abstract] [Full Text] [Related]
19. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma.
Cheng Y; Wang K; Geng L; Sun J; Xu W; Liu D; Gong S; Zhu Y
EBioMedicine; 2019 Feb; 40():382-393. PubMed ID: 30639415
[TBL] [Abstract][Full Text] [Related]
20. Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells.
Winter U; Mena HA; Negrotto S; Arana E; Pascual-Pasto G; Laurent V; Suñol M; Chantada GL; Carcaboso AM; Schaiquevich P
PLoS One; 2016; 11(7):e0160094. PubMed ID: 27467588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
